PLA2G7 and diabetes mellitus: Currently, animal experiments and clinical trials involving an Lp-PLA2 inhibitor (darapladib) are underway and have been shown to reduce the progression of atherosclerosis in animals [21, 22] but not in humans [23] with or without diabetes.